UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date
of Report (Date of earliest event reported): July 28, 2020
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Nevada
|
|
000-54554
|
|
45-1226465
|
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
4093 Oceanside Boulevard, Suite B
|
|
Oceanside, California 92056
|
|
(Address of Principal Executive Offices and Zip Code)
|
|
|
|
(760) 295-7208
|
|
(Issuer's telephone number)
|
|
|
|
Not
Applicable
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events.
On
July 28, 2020, Therapeutic Solutions International, Inc. filed U.S.
Patent Application No.: 63/057315 titled "Neuroprotection and
Neuroregeneration by Pterostilbene and Compositions Thereof" and
issued a press release titled “Therapeutic Solutions International
Files Patent on Ability of QuadraMune Ingredient Pterostilbene to
Reduce Inflammation while Stimulating Brain Protective Biological
Pathways” attached here as exhibit.
Item 9.01 Financial Statements and Exhibits.
Exhibit Index
(99)
Press release dated July 28, 2020, issued by Therapeutic Solutions
International, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date:
July 28, 2020
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
By:
/s/ Timothy
Dixon
Timothy Dixon
Chief
Executive Officer
